Influence of Late Vascular Inflammation on Long-Term Outcomes Among Patients Undergoing Implantation of Drug Eluting Stents: Role of C-Reactive Protein.
BACKGROUND
Elevation of C-reactive protein (CRP) as a marker of vascular inflammation at a late phase of drug-eluting stent (DES) implantation may predict subsequent major adverse cardiac events (MACE).


RESULTS
In 1234 consecutive patients undergoing DES implantation, CRP was measured both before (baseline) and 8 to 12 months after (late phase) stenting, and the relationship between elevation of CRP (>2.0 mg/L) and subsequent MACE (all cause death, nonfatal myocardial infarction, target lesion revascularization, and other additional revascularization) was assessed. As results, CRP was elevated in 38.0% of patients at baseline and in 23.6% during late phase (P<0.0001), and hazard ratio (HR) for MACE was 1.52 (95% confidence interval [95% CI] 1.21-1.93, P=0.0004) at baseline versus 4.00 (95% CI 3.16-5.05, P<0.0001) in late phase. By multivariable analysis, late-phase CRP elevation (HR 3.60, 95% CI: 2.78-4.68, P<0.0001), chronic kidney disease (CKD) (HR 1.41, 95% CI: 1.10-1.84, P=0.01), and number of diseased segments (HR 1.19, 95% CI: 1.08-1.30, P=0.0002) were positive predictors of MACE, whereas statin use (HR 0.66, 95% CI 0.50-0.87, P=0.003) was a negative predictor. Propensity score-matched analysis also confirmed the effect of late-phase CRP on MACE (HR 3.39, 95% CI 2.52-4.56, P<0.0001). In prediction of the late-phase CRP elevation, CKD (odds ratio [OR] 1.71, 95% CI 1.24-2.36, P=0.001) and baseline CRP elevation (OR 3.48, 95% CI 2.55-4.74, P<0.0001) were positive predictors, whereas newer generation DES (OR 0.59, 95% CI 0.41-0.84, P=0.003) and statin therapy (OR 0.68, 95% CI 0.47-0.97, P=0.03) were negative predictors.


CONCLUSIONS
Monitoring the late-phase CRP may be helpful to identify a high-risk subset for MACE among patients undergoing DES implantation.
Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan masanorishiba@hotmail.com.
Masanori
M
Shiba
Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.
Hideki
H
Itaya
Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.
Raisuke
R
Iijima
Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.
Masato
M
Nakamura
C‐reactive protein; drug‐eluting stent; long‐term outcome
Am J Kidney Dis. 2009 Jun;53(6):982-92
19339088
J Am Coll Cardiol. 2006 Jan 3;47(1):175-81
16386683
Circulation. 2012 Jan 31;125(4):584-91
22203694
Circulation. 2009 Aug 4;120(5):391-9
19620501
Am J Epidemiol. 2006 Feb 1;163(3):262-70
16371515
EuroIntervention. 2016 Dec 10;12 (11):e1366-e1374
26690315
Am J Cardiol. 2012 May 15;109 (10 ):1387-96
22381164
Circ J. 2012;76(11):2561-71
22878407
Heart. 2010 May;96(10):756-64
20448126
J Am Coll Cardiol. 2005 Jul 19;46(2):239-45
16022949
Ann Intern Med. 2012 Aug 21;157(4):263-75
22910937
J Am Coll Cardiol. 2012 Jun 5;59(23 ):2051-7
22651862
Nat Rev Cardiol. 2012 May 22;9(8):439-53
22614618
JACC Cardiovasc Interv. 2011 Jan;4(1):123-8
21251639
Clin J Am Soc Nephrol. 2009 Feb;4(2):291-8
19144763
Circulation. 2014 Jan 14;129(2):211-23
24163064
N Engl J Med. 2005 Jan 6;352(1):20-8
15635109
J Am Coll Cardiol. 2010 Nov 23;56(22):1783-93
21087705
Am J Cardiol. 2011 Jan 15;107(2):179-85
21129710
Lancet. 2014 Jun 14;383(9934):2047-56
24631162
Kidney Int. 2005 Aug;68(2):766-72
16014054
N Engl J Med. 2009 Apr 2;360(14):1395-407
19332456
Circulation. 2007 May 1;115(17):2344-51
17470709
N Engl J Med. 2008 Nov 20;359(21):2195-207
18997196
Circulation. 2008 Sep 9;118(11):1138-45
18725485
J Am Coll Cardiol. 2010 Aug 31;56(10 Suppl):S43-78
20797503
Am J Cardiol. 2012 Dec 1;110(11):1568-77
22935527